Phase II trial of pepinemab in Huntington’s disease does not meet primary endpoints

Although the results of two cognitive assessments from the Huntington’s Disease Cognitive Assessment Battery and Clinical Global Impression of Change showed a strong trend for beneficial change, the primary endpoints were not met. Drug also being developed for use in Alzheimer’s.

Source:

Biospace Inc.